Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,665,531
  • Shares Outstanding, K 152,665
  • Annual Sales, $ 178,960 K
  • Annual Income, $ -159,490 K
  • EBIT $ -76 M
  • EBITDA $ -65 M
  • 60-Month Beta 2.20
  • Price/Sales 14.61
  • Price/Cash Flow N/A
  • Price/Book 12.77

Options Overview Details

View History
  • Implied Volatility 118.92% (+0.88%)
  • Historical Volatility 92.52%
  • IV Percentile 75%
  • IV Rank 32.13%
  • IV High 247.56% on 02/03/25
  • IV Low 58.02% on 06/13/25
  • Expected Move (DTE 13) 3.06 (20.75%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 318
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 2,664
  • Open Int (30-Day) 3,136
  • Expected Range 11.69 to 17.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.28 +11.07%
on 11/18/25
20.76 -28.95%
on 11/25/25
-2.84 (-16.15%)
since 11/05/25
3-Month
12.34 +19.53%
on 09/10/25
20.76 -28.95%
on 11/25/25
+1.90 (+14.79%)
since 09/05/25
52-Week
5.80 +154.09%
on 12/19/24
20.76 -28.95%
on 11/25/25
+8.68 (+143.00%)
since 12/05/24

Most Recent Stories

More News
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies: Q3 Earnings Snapshot

Adaptive Biotechnologies: Q3 Earnings Snapshot

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 14.75 (-15.52%)
Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum. Shares are up 250% in the past year and just hit a new three-year high. ADPT maintains a 100% “Buy” opinion...

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 14.75 (-15.52%)
Is Bio-Techne Stock Underperforming the Dow?

Bio-Techne has significantly underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.

TECH : 61.68 (-2.93%)
ADPT : 14.75 (-15.52%)
$DOWI : 47,954.99 (+0.22%)
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies: Q2 Earnings Snapshot

Adaptive Biotechnologies: Q2 Earnings Snapshot

ADPT : 14.75 (-15.52%)
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 14.75 (-15.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 17.38
2nd Resistance Point 16.82
1st Resistance Point 15.78
Last Price 14.75
1st Support Level 14.18
2nd Support Level 13.62
3rd Support Level 12.58

See More

52-Week High 20.76
Fibonacci 61.8% 15.05
Last Price 14.75
Fibonacci 50% 13.28
Fibonacci 38.2% 11.52
52-Week Low 5.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar